Global inactivation of carboxylesterase 1 (Ces1/Ces1g) protects against atherosclerosis in Ldlr−/− mice

被引:0
|
作者
Jiesi Xu
Yang Xu
Yanyong Xu
Liya Yin
Yanqiao Zhang
机构
[1] Northeast Ohio Medical University,Department of Integrative Medical Sciences
[2] Institute of Genetics and Developmental Biology,State Key Laboratory of Molecular Developmental Biology
[3] Chinese Academy of Sciences,undefined
来源
Scientific Reports | / 7卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Atherosclerotic cardiovascular disease is a leading cause of death in the western world. Increased plasma triglyceride and cholesterol levels are major risk factors for this disease. Carboxylesterase 1 (Ces1/Ces1g) has been shown to play a role in metabolic control. So far, the role of mouse Ces1/Ces1g deficiency in atherosclerosis is not elucidated. We generated Ces1/Ces1g−/− mice. Compared to wild-type mice, Ces1/Ces1g−/− mice had reduced plasma cholesterol levels. We then generated Ces1g−/−Ldlr−/− double knockout (DKO) mice, which were fed a Western diet for 16 weeks. Compared to Ldlr−/− mice, DKO mice displayed decreased plasma cholesterol and TG levels and reduced atherosclerotic lesions. Interestingly, knockdown of hepatic Ces1/Ces1g in Apoe−/− mice resulted in hyperlipidemia and exacerbated Western diet-induced atherogenesis. Mechanistically, global inactivation of Ces1/Ces1g inhibited intestinal cholesterol and fat absorption and Niemann-Pick C1 like 1 expression, and increased macrophage cholesterol efflux by inducing ATP-binding cassette subfamily A member 1 (ABCA1) and ABCG1. Ces1/Ces1g ablation also promoted M2 macrophage polarization and induced hepatic cholesterol 7α-hydroxylase and sterol 12α-hydroxylase expression. In conclusion, global loss of Ces1/Ces1g protects against the development of atherosclerosis by inhibiting intestinal cholesterol and triglyceride absorption and promoting macrophage cholesterol efflux.
引用
收藏
相关论文
共 50 条
  • [1] Global inactivation of carboxylesterase 1 (&ITCes1/Ces1g&IT) protects against atherosclerosis in &ITLdlr&IT-/- mice
    Xu, Jiesi
    Xu, Yang
    Xu, Yanyong
    Yin, Liya
    Zhang, Yanqiao
    SCIENTIFIC REPORTS, 2017, 7
  • [2] Sacubitril is selectively activated by carboxylesterase 1 (CES1) in the liver and the activation is affected by CES1 genetic variation
    Shi, Jian
    Wang, Xinwen
    Nguyen, Jenny
    Wu, Audrey
    Bleske, Barry
    Zhu, Hao-Jie
    FASEB JOURNAL, 2016, 30
  • [3] Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation
    Shi, Jian
    Wang, Xinwen
    Nguyen, Jenny
    Wu, Audrey H.
    Bleske, Barry E.
    Zhu, Hao-Jie
    DRUG METABOLISM AND DISPOSITION, 2016, 44 (04) : 554 - 559
  • [4] Carboxylesterase 1 (Ces1): from monocyte marker to major
    Markey, Geraldine M.
    JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (02) : 107 - 109
  • [5] Carboxylesterase 1 (CES1) genetic polymorphisms and oseltamivir activation
    Hao-Jie Zhu
    John S. Markowitz
    European Journal of Clinical Pharmacology, 2013, 69 : 733 - 734
  • [6] Carboxylesterase 1 (CES1) genetic polymorphisms and oseltamivir activation
    Zhu, Hao-Jie
    Markowitz, John S.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (03) : 733 - 734
  • [7] Regulation of carboxylesterase 1 (CES1) in human adipose tissue
    Jernas, Margareta
    Olsson, Bob
    Arner, Peter
    Jacobson, Peter
    Sjostrom, Lars
    Walley, Andrew
    Froguel, Philippe
    McTernan, Philip G.
    Hoffstedt, Johan
    Carlsson, Lena M. S.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 383 (01) : 63 - 67
  • [8] Bioactive lipid metabolism by carboxylesterase 1 (CES1) in macrophages
    Mangum, Lee
    Borazjani, Abdolsamad
    Crow, John
    Ross, Matthew
    FASEB JOURNAL, 2014, 28 (01):
  • [9] The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans
    Yuki Suzaki
    Naoto Uemura
    Makoto Takada
    Tetsuji Ohyama
    Akiko Itohda
    Takuya Morimoto
    Hiromitsu Imai
    Hajime Hamasaki
    Akihiro Inano
    Masakiyo Hosokawa
    Masato Tateishi
    Kyoichi Ohashi
    European Journal of Clinical Pharmacology, 2013, 69 : 21 - 30
  • [10] The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans
    Suzaki, Yuki
    Uemura, Naoto
    Takada, Makoto
    Ohyama, Tetsuji
    Itohda, Akiko
    Morimoto, Takuya
    Imai, Hiromitsu
    Hamasaki, Hajime
    Inano, Akihiro
    Hosokawa, Masakiyo
    Tateishi, Masato
    Ohashi, Kyoichi
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (01) : 21 - 30